IASR J. Med. Pharm. Sci.
ISSN: 2582-9343
Website: https://ijmps.com/
Open Access Journal
Country: India

IASR Journal of
Medical and
Pharmaceutical Science

ORIGINAL ARTICLE OPEN ACCESS

Designing the Future of Pharmacy: 3D Printing Multi-Drug Dosage Forms in a Single Unit Dose for Multiple Diseases

Ajay Yadav[1*]; Shekhar Singh[2]; Vishal Rai[3]

[1,2,3]Suyash Institute of Pharmacy, Hakkabad, Gorakhpur, Uttar Pradesh, India

OPEN ACCESS

Corresponding Author
Ajay Yadav
Suyash Institute of Pharmacy, Hakkabad, Gorakhpur, Uttar Pradesh, India.

Received: 15-09-2024
Accepted: 24-10-2024
Available online: 25-11-2024

ABSTRACT

As the rise in chronic diseases prevalence continues, so does the increasing necessity of polypharmacy, which in turn challenges adherence compliance, drug interactions, and tailored dosing. 3D Printing in Pharmaceutical Industry. This technology of designing and manufacturing multi-drug dosage forms into one single customized unit holds promise. This paper looks at the technological advancements, preparation methods, and clinical utilization of 3D printing in multi-drug delivery with a focus on applying the method to the multifaceted issue of polypharmacy of delivering multiple drugs in one single, specific dose with individualized release profiles. Some of the main chapters include the types of 3D printing methods available in pharmaceuticals, like Fused Deposition Modeling (FDM), Selective Laser Sintering (SLS), and issues related to material selection as well as problems associated with the layering of drugs for controlled release. In addition, pharmacokinetic and pharmacodynamic considerations have also been made whereby the accuracy of 3D printing is associated with drug absorption, metabolism, and interaction in a single dose of medication. The possible future use of such complexity in multi-drug treatments, which could be made for cardiovascular diseases, diabetes, and neurological disorders, could increase benefits for the most vulnerable: the elderly and pediatric populations suffering from polypharmacy problems. Regulatory and ethical aspects are posed to call attention to a need to address quality control and patient safety standards before commercialization of 3D printed multi-drug products. In this regard, the article outlines the directions toward integrating nanotechnology and artificial intelligence for more personalised dosing in the future. The integration of all the research up to date as well as the discussion of the challenges for the future portrays that 3D printing holds the potential of transforming the pharmacy practice into a safer and more effective treatment for patients.

Key Words: *Antibiotic Resistance; Multidrug-Resistant Pathogens; Antimicrobial Stewardship; Phage Therapy*

1. Introduction

Overview of Polypharmacy in Chronic Diseases

Polypharmacy is defined as the co-medication of multiple drugs by one patient. It is a common scenario when chronic diseases are being managed, where one condition requires more than one drug to control symptoms and prevent complications of a disease. Multi-drug therapies have become very necessary for some chronic conditions, including cardiovascular diseases, diabetes, and mental health disorders, thus raising the burden of pills on patients and accompanied with several issues related to adherence (Alomar et al., 2020). For instance, patients with hypertension would need antihypertensives, antidiabetics, and lipid-lowering agents among others. This makes the treatment regime often to be complex and time-consuming. High volume of medication does not only cause problems in compliance but increases ADEs. ADEs frequently occur in elderly patients since the compounded effects of polypharmacy on metabolism and drug interactions amplify the risk (Maher et al., 2014).

Challenges currently being faced by multiple medications

Alongside adherence, the challenges of polypharmacy are managing several medications. Polypharmacy has been linked to a higher risk of drug-drug interactions, which in some cases may lead to reduced efficacy or increased toxicity because of synergistic effects of drugs (Kaduszkiewicz et al., 2019). Furthermore, the cognitive and physical demands required in managing complex medication schedules act as a precursor to poor health outcomes and nonadherence. All adjunct medications raise the regimen complexity and further opportunities for both voluntary and involuntary omissions that are at uniquely high risk for patients with impaired cognition or limited support network (Gellad et al., 2017). Risk reduction with multifaceted preservative of efficacy in multi-drug regimens has found significant headline appeal in personalized medicine because it continues to research alternative drug delivery systems for simplification of administration.

Emerging Role of 3D Printing in Personalized Medicine

3D printing, or additive manufacturing, is an emerging technology for personalized medicine, which has transformed the field of drug delivery systems to be customized according to an individual's requirement (Wang et al., 2016). In contrast to conventional approaches, the formulation of 3D printing makes possible the inclusion of multiple drugs into one unit. This capability, therefore, aligns with goals in personalized medicine, offering a more patient-centered approach that can be tailored to the particular needs of the individual with a complicated therapeutic regimen. The ability of 3D printing to allow healthcare providers to adjust the drug composition, dosage, and release profiles can drastically reduce pill burden and enhance compliance in patients requiring polypharmacy (Khaled et al., 2018). This technology not only streamlines medication management but also allows the development of more effective treatments by targeted drug release and multi-drug therapies into single-dose forms.



2. 3D Printing in Pharmaceuticals

Evolution of 3D Printing Technology

3D printing, that was originally developed in the 1980s as rapid prototyping technology, has become a highly versatile tool spanning across industries to encompass healthcare and pharmaceuticals. This process is known as additive manufacturing and is used to create products layer upon layer from digital models. Consequently, the size and shape of the product, as well as its internal structure, are highly controlled (Ventola, 2014). Three-dimensional printing has gained popularity in the pharmaceutical field because it can be used to obtain complex drug formulations and dosage forms that were not easily achievable with conventional manufacturing methods (Norman et al., 2017). This technology supports progress in personalized medicine as medication can be designed to be customized for individual needs in drug combinations, dosages, and controlled-release profiles (Alhnan et al., 2016).

3D Printing Techniques Used in Drug Development

There are many 3D printing technologies that have been adapted for pharmaceutical use, each with unique properties conducive to tailored drug delivery system manufacturing. Some of these are the FDM, SLA, SLS, and Inkjet Printing. Each of these has a very distinct character, therefore possible in drug-making.

Fused Deposition Modeling (FDM)

Fused Deposition Modeling is one of the chief 3D printing techniques that can be readily used in pharmacy because it is cost-effective and easy to use. Essentially, the technique involves extruding a thermoplastic filament through a heated

nozzle to deposit material layer by layer, thus creating a solid structure which may be tailored in relation to drug dose and release profile (Jamróz et al., 2018). According to Pérez-López et al. from 2021, FDM is especially appropriate for the fabrication of dosage forms as it will alter both the material composition and the arrangement of layers that demonstrate modified-release properties.

Stereolithography

Stereolithography is the technique that employs UV light in order to selectively cure a photosensitive resin, layer by layer, to form a solid object. SLA is applied for high resolution and the capacity of making designs with highly delicate details. It is appropriate in the manufacture of tiny drug delivery devices that are well set (Martinez et al., 2017). This can particularly be very helpful in the tablets for the constructions of geometries which contain the governing drug release properties. It can also be applied for multi-drug preparations in one dose.

Selective Laser Sintering (SLS)

A laser sintering technology referred to as Selective Laser Sintering (SLS) does not use binder and/or solvents as it melts powders using a laser with the formation of a solid structure. SLS possesses the special benefit of formulating with thermolabile drugs; this process does not exhibit thermal degradation since it functions at relatively low temperatures (Tan et al., 2018). In addition, SLS facilitates the production of porous structures within tablets such that specific drug release profiles can be designed with controlled porosity in the processing (Fina et al., 2017).

Inkjet Printing

Inkjet printing technology directly prints API on substrates or makes up multilayered dosage units. It delivers drug-specific, precise depositions apt for personalized dosages (Buanz et al., 2011). The advantages of inkjet printing include dose flexibility and the ability to administer a formulation comprising multiple drugs, which supports customized and patient-specific therapies (Li et al., 2020).

3D Printed Drugs Approved by FDA

The biggest milestone in pharmaceutical manufacturing was, perhaps, the nod given by the U.S. Food and Drug Administration (FDA) in 2015 to the very first 3D printed drug, Spritam ® for the drug levetiracetam. It was developed by Aprecia Pharmaceuticals making use of ZipDose ® technology-which is one mode of employing 3D printing that produces a highly porous tablet so that it disintegrates very rapidly once it comes into contact with liquid, assisting patients who have difficulty or cannot swallow conventional tablets (U.S. Food and Drug Administration, 2015). This approval has generated interest in further research and development on 3D printed drugs since this demonstrates the capability of 3D printing to address needs of specific patients by developing customized dosage forms and enhancing bioavailability (Norman et al., 2017).



3. Development of Multi-Drug Dosage Forms

Multi-Drug Unit Dose (MDUD) Concept

What MDUD brings about is a new concept in pharmaceutical design because it will now allow multiple APIs to be combined into a single dosage form. This is a promising method that capitalizes on the potency of 3D printing in being

able to combine diverse APIs with different release profiles into a single structure. MDUDs are also very advantageous to polypharmacy patients since they can combine complex regimens into one tablet or capsule that makes its administration easier and reduces the burden of managing various medications daily (Goyanes et al., 2015). This idea, in addition to promoting adherence, also decreases the number of erroneous or missed doses among patients with chronic conditions, as their regimens are complex and considered very difficult to keep track of (Norman et al., 2017).



Advantages of Multi-Drug Dosage Forms for Polypharmacy Patients

Patients with polypharmacy, particularly those with multiple chronic diseases, commonly suffer from problems that involve drug complexity, adherence, and side effects. One way of consolidated multi-drug dosage form address such issues is by having drugs combined under one dosage form, thus making it easier for patients to take their prescribed therapies consistently. Research has demonstrated that simplification of medication regimens through such unified dosage forms aids in improved adherence and, hence, outcomes clinically (Alomari et al., 2015). Moreover, the MDUD system can even provide controlled, sequential release profiles in a single tablet, hence ensuring that each drug is released at the required site and time in the body, an aspect that further enhances therapeutic effectiveness with minimal adverse effects (Khaled et al., 2018).

Challenge in Formulation and Drug Compatibility

Despite the benefits of MDUDs, however several challenges occur when it comes to their formulation. One of the major drug compatibility issues occurs with a number of drugs combined, having diverse chemical and physical properties, stability problems, and unwanted interactions that derogate efficacy and safety (Goyanes et al., 2015). Moreover, exact dosing accuracy of each active ingredient within a single dose cannot be maintained; even different drugs may require a separate release mechanism or can undergo degradation under the same environmental conditions (Awad et al., 2019). Multi-drug dosage forms further require the evolution of advanced printing techniques and wise selection of excipients to prevent interferences and stabilize APIs while offering the necessary profiles of release, which makes this approach a complicated procedure (Genina et al., 2016).

4. Technical Aspects of 3D Printing Multi-Drug Dosage Forms

Drug Layering and Spatial Distribution

When preparing effective multi-drug dosage forms through 3D printing, drug layering and spatial distribution must be paid particular attention. This process is called multilayering API wherein several APIs are layered in a single dosage unit so that the drug of interest takes the place in the desired therapeutic profile. Then there can be an alteration of the spatial arrangement of the drug in a hope to control API--api interaction and release profile. The effective spatial distribution minimizes drug-drug interaction, which remains one of the factors for the polypharmacy patients having complex regimens (Awad et al., 2019). This customization enables a more accurate and efficient drug delivery, hence, every layer of medication can be administered over some specific release times or under physiological conditions based on patients' needs (Jamróz et al., 2018).

Customization of Release Profiles

3D printing technology makes it possible to customize release profiles in multi-drug dosage forms. Thus, through this technology, tablets can be engineered with immediate, sustained, and delayed release layers. These layers can be prepared to provide actives sequentially, thereby delivering much therapeutic benefit and convenience to the patient. Immediate-release layers allow drugs to be absorbed rapidly and result in rapid relief. Sustained-release layers provide drug delivery over an extended period, ensuring that therapeutic levels are maintained. Delayed release layers ensure drugs are activated only after a predetermined time or in particular districts of the GI tract (Goyanes et al., 2015). Customizing these release profiles with 3D printing allows for better flexibility in the delivery of drugs, tailoring medication schedules to suit the needs of numerous chronic disease patients. Application in Instant, Sustained, and **Delayed Release Layers**

It is envisioned that this combination of an immediate release layer, sustained release layer, and delayed release layer be incorporated in a single dosage unit that presents unique advantages. The immediate release layer is very helpful in rapid onset of action when sometimes the drug needs to be rapidly absorbed. The sustained-release layers have drugs remain steadily in the body over time, hence reduced dosing frequency leading to better adherence. Delayed-release layers are applicable to drugs that require activation within specific regions of the gastrointestinal tract, for example, enteric-coated tablets and capsules that allow release only once they pass through the stomach acidic environment (Khaled et al., 2018). All these layers within a unit can prove useful in satisfying complicated therapeutic regimens for superior clinical outcomes and patient satisfaction.

Material selection compatibility with biodegradability

Selection of material appropriate for 3D-printed multi-drug dosage forms is highly essential with regard to stability, biocompatibility, and controlled release of drugs. Materials, for instance, most commonly used are polymers like PVA and HPMC; these are well known in the industry for their ability to get adjusted degradation rates along with being compatible with drugs in such forms (Goyanes et al., 2017). These rely on the selection of materials, as oral administration requires steady release of active ingredients without any compromise for dosage accuracy. Other materials used in 3D printing allow pH-sensitive or temperature-sensitive release of drugs, which would provide further control mechanisms according to physiological conditions. (Awad et al., 2019).

Process Parameters Affecting Drug Stability and Dosage Accuracy

Some of the critical factors in drug stability and accurate dosage include process parameters: printing temperature, speed, layer thickness, and calibration of the printer. For example, elevated temperatures are necessary in processes that use FDM. Regarding this, the degradation of drugs based on heat sensitivity may compromise their effectiveness. This risk can be mitigated through adjustment of parameters such as print speed and layer thickness to ensure uniform dosages (Jamróz et al., 2018). Moreover, uniform drug distribution in printed layers is essential so that any possible nonuniformity may lead to dose variance and thus affect therapeutic effects (Genina et al., 2018). Micromanaging such parameters is essential for guaranteeing the safety and efficacy of multi-drug dosage forms printed 3D.



5. Pharmacokinetics and Pharmacodynamics of 3D Printed Multi-Drug Forms

Layered drug delivery and its impact on absorption and metabolism

This layered structure of multi-drug dosage forms 3D printed allows precise control of the rates of drug release and, therefore, affects the pharmacokinetics of all medications in the dose—absorption, distribution, metabolism, and excretion. Allowing staggered times for absoption of different drugs, structuring immediate, sustained, and delayed-release layers in 3D-printed dosage forms enhances bioavailability and achieves the best therapeutic plasma concentrations (Khaled et al., 2018). This controlled release is particularly beneficial for drugs that have uneven absorption rates. At such points where each drug layer will dissolve, it is at a particular point within the gastrointestinal tract, matched with physiological

conditions that allow maximum absorption (Goyanes et al., 2015). Such an approach helps to reduce peak plasma levels of certain drugs, thus allowing for minimal side effects and smoother pharmacokinetic profiles.

Control of Drug-Drug Interactions within a single unit dose

Preventing adverse drug-drug interactions is a significant challenge for multi-drug forms. Such interactions may work against both the efficacy and safety of the treatment. In the conventional concept of polypharmacy, single doses of various drugs would be interacting with each other in the gastrointestinal tract and blood stream, but in a dosage form printed by 3D printing, drugs could be compartmentalized in one unit, which may reduce such reactions to some extent. Isolating each API in a separate layer thus minimizes the possibilities of incompatible drugs reacting in the dosage form. However, the presence of interactions would be shown to be excluded through proper pharmacodynamic and pharmacokinetic testing, including drug activity without interaction at the intended level of efficacy (Norman et al., 2017). Then, the layered configuration can upgrade the pharmacokinetic modeling in providing predictions of the interaction potential to allow for preclinical adjustments in ensuring the drug release and absorption sequences are safer to avoid adverse side effects (Alomari et al., 2015).

Prediction and Testing Therapeutic Efficacy and Safety

This multi-drug 3D-printed dosage form will be tested extensively for therapeutic efficacy and safety in both in vitro and in vivo testing. Through such in vitro dissolution testing, release patterns are predicted and mimicked for gastrointestinal testing conditions to confirm that each drug layer has been released according to their intended function. Additional information in vivo assessment will determine exactly how the layered drugs interact with the body, providing assurance that bioequivalence to traditional dosage forms is preserved. Pharmacodynamic outcomes of the combination, such as therapeutic efficacy and adverse effects of these drugs, would be determined by preclinical and clinical trials. Predictive pharmacokinetic modeling would help in designing an optimal release profile to avoid adverse interactions while maintaining therapeutic levels of each drug in MDUD (Goyanes et al., 2015). The approval of those dosage forms relies on the safety and efficiency as well as on experimental and simulation studies (Jamróz et al., 2018).



6. Clinical Applications and Disease Management

Single-Dose Polypharmacy

3D printed multi drug dosage forms are particularly useful in the treatment of chronic diseases, most of which are needed to be treated with polypharmacy. These dosage forms simplify complicated dosing regimens because multiple drugs can be combined in a single unit dose, thus reducing pill burden and enhancing adherence for patients. The overall benefits apply especially to patients suffering from many chronic diseases like diabetes, hypertension, and cardiovascular disorders because, in addition to minimizing the risk of missed doses, this approach also aids in optimizing the outcome of therapy. Formulations streamlined to the particular needs of each patient are very beneficial for those dealing with complications of polypharmacy that necessitate a streamlined experience of medication (Alhijjaj et al., 2016).

Management of Hypertension, Diabetes, and Cardiovascular Disease

Chronic diseases such as hypertension, diabetes, and cardiovascular disease commonly coexist. Therefore, pharmacotherapy must be broad-based and ongoing. A single-dose, multi-drug format allows for the management of various classes of medications, such as antihypertensives, antidiabetic agents, and lipid-lowering drugs, all at once within

one tablet (Khaled et al., 2018). This approach addresses not only the individual diseases but also improves the overall management of these interrelated diseases. Such formulations can manage steady plasma drug concentrations while preventing risks from frequently fluctuating levels associated with traditional dosing, since it can tailor the release properties for each medication (Goyanes et al., 2015).

Infectious Diseases and Multi-Antibiotic Therapy

Since a dosage form can be customised to contain more than one antibiotic, 3D printing of a multi-antibiotic may be an efficient strategy to treat patients suffering from infectious diseases. As the antibiotic resistance evolves, then administering multiple drugs at once in a single dose can provide an improvement in treatment efficacy. It can simultaneously attack pathogens through various mechanisms of action (Jamróz et al., 2018). Moreover, with 3D printing, the ordered sequence of drug release could be optimized to minimize cross-resistance and thus better patient outcomes for infectious diseases. The potential for changing dosing forms of antibiotics also allows for more precise dosing, which is important in achieving the therapeutic index required for the eradication of bacteria without toxicity(Norman et al., 2017).

Neurological and Psychiatric Diseases

Most neurological and psychiatric diseases, such as epilepsy, depression, and schizophrenia, are managed by combinations of drugs, where many have varied release profiles in order to help manage symptoms effectively. Immediate and sustained-release layers, 3D-printed dosage forms can help produce stable plasma levels of antipsychotics, mood stabilizers, or anticonvulsants with reduced side effects and greater control of symptoms. For example, stable dosing in epilepsy treatment could reduce the risk for breakthrough seizures. It has advantages for psychiatric patients in aiding better medication adherence and reducing drug level fluctuations that can induce exacerbation of the symptoms (Alomari et al., 2015).

Elderly and Pediatric Patient Uses

Swallowing problems, including complex dosage regimens, make the administration of conventional polypharmacy very challenging for elderly and pediatric patients. The multi-drug 3D-printed dosage form provides an effective answer for consolidating multiple medications into a single, easy-to-swallow unit. These could be designed to take into account age-related pharmacokinetic alterations and thus enhance drug absorption, with subsequent decreases in side effects (Khaled et al., 2018). For pediatric therapy dosing can be attained precisely for their age and weight. This would ensure safety and efficacy would increase, but the administration of several tablets or syrups would be eliminated. (Goyanes et al., 2015).



7. Regulatory and Ethical Considerations

Regulatory Framework for 3D Printed Drugs

Therefore, the advent of 3D printing in pharmaceuticals is making its way into regulatory frameworks where traditional norms are adjusted to suit this emerging technology. The FDA in the United States already authorized a few 3D-printed drugs but in huge numbers of other drugs for generations that come after it. The development, customization, and demand-based formulation of drugs, however, present many challenges for regulators on the standard manufacturing requirements, quality control measures, and assurances of reproducibility. Some of the relevant regulatory considerations that would be in place were GMP compliance and all printed batches would have the same drug concentration, stability, and bioavailability (Awad et al., 2019). Pre-established policies are currently under way by regulatory agencies globally as a step to meet these challenges that 3D printing of drugs poses differently.

Quality Control and Assurance in Multi-Drug Printing

Quality control of multi-drug 3D-printed dosage forms is essential primarily because accurate drug layering and spatial distribution would determine the desired therapeutic effects. Standards quality assurance (QA) measures are almost impossible to apply to products because of their complex structure and their multi-drug nature. Uniformity in each dose and consistent release profiles are very important in therapeutic efficacy and minimizing adverse effects (Goyanes et al., 2015). Advanced quality control techniques, such as in-line monitoring and ex line analysis, are increasingly being researched for the manufacture of 3D printing with stringent quality assurances. All these techniques can prove that drugs are stable; that compatibility is evaluated; and that every layer of drugs will meet strictly essential levels of quality. Thus, quality assurance becomes a concern to both manufacturers and regulators (Khaled et al., 2018).

Patients' Safety and Ethical Consideration

In the development of multi-drug 3D-printed formulations, patient safety should be the first consideration. Many emerging manufacturing processes have their own safety concerns. So, multi-drug dosage forms should be designed in such a way that it doesn't lead to any drug-drug interactions within the same dose and it must have a guaranteed release profile tailored to the patient's requirement (Alhijjaj et al., 2016). Innovation and safety must be accompanied by ethical considerations, particularly with the speed at which 3D printing technology is developed. Regulatory and safety evaluation cannot catch up with this. Another challenge worth ethical consideration is equitable access to such advanced formulations. For instance, some advanced 3D-printed medications may be cost-prohibitive, placing them under prohibitions that limit their availability to particular populations of patients. Continuous exposure to ethical considerations such as transparency, consent, and access will thus be an essential aspect as 3D-printed medicines begin to feature more significantly in a physician's daily practice (Jamróz et al., 2018).



8. Future Trends and Advances

3D Printing: Smart Drug Delivery Systems

The future of personalized medicine has a very high potential as it would be integrated with smart drug delivery systems through 3D printing. Based on an integration between sensors and responsive materials with 3D-printed drug formulations, it is thus possible to design drug delivery systems that have the ability to vary the release profile according to physiological feedback. They could change in response to pH or temperature or some specific biomarkers, thereby controlling the medication's controlled release in tandem with the needs of the body. The development of such "smart" systems can even transform the drug management process by enabling better efficacy of drugs, reduced side effects, and improved patient compliance particularly for chronic and complex diseases (Norman et al., 2017).

Nanotechnology Applications in 3D Printed Drugs

The applications of nanotechnology within 3D-printed drugs open up avenues for controlled drug delivery. Nanoparticles can be incorporated into 3D-printed formulations, which enables targeted delivery and improved solubility and release properties (Jamróz et al., 2018). The nanotechnology-enabled 3D-printed medications can enhance the degree of therapeutic effect in collaboration with reducing side effects by offering high accuracy for drugs and formulations with

precision targeting towards specific cells or tissues. Nano-enable formulations also offer multi-layered and multi-compartmental designs, embedded in a matrix of active agents at different speeds or under diverse triggers, suitable to handle multi-drug regimens in complex diseases (Khaled et al., 2018).

Artificial Intelligence in Drug Design and Customization

AI's innovative potential in drug design and engineering deals with searching through enormous amounts of information to improve the formulation of drugs, foresee patient response, and individualise dosages. An AI algorithm can, therefore, accompany pharmacokinetics, pharmacodynamics, and patient-specific requirements to tailor well-designed pharmaceutical drugs toward meeting the person's unique therapeutic needs (Trenfield et al., 2019). Additionally, the AI provides acceleration to formulate drugs through machine learning so that timelines and costs associated with developing drugs can be reduced. Thus, synergies between AI and 3D printing support really high personalization of medicine in line with goals of treatment for patients.

Personalised Dosage Forms for Real-Time Health Monitoring

The advancement of digital health technology is seen through the real-time monitoring of health conditions, and when combined with 3D printing, new doors unlock to dynamic and responsive formulations of drugs. Health metrics like blood glucose, blood pressure, or even oxygen levels can be monitored with wearable or implantable sensors that then give instant feedback for dosage adjustment (Awad et al., 2019). These data-driven systems can be incorporated with 3D-printed, customized dosage forms that will allow on-demand alteration in medication, maximize the flexibility in therapy treatment, and optimize outcomes. Such real-time, individualized dosing systems are best suited to proactive and responsive health care-the challenges to be faced in managing chronic conditions in a more patient-centered approach.



9. Challenges and Limitations

Manufacturing Scalability and Cost Considerations

One of the advantages of 3D printing is its ability to produce highly customised formulations, and yet, scalability is one of its significant challenges. Most of the existing 3D printing technologies are expensive and time-consuming especially when it comes to replication in large quantities of personalized medicines. Materials such as polymers, bioinks, and drug-loaded matrices used in 3D printing can also be expensive, adding to production costs (Goyanes et al., 2015). Furthermore, the available printing technology may not be aimed at manufacturing high-volume production. Thus, its applicability in large-scale production is still limited because of this. More research is being focused on developing materials that are less expensive in development, simplified manufacturing processes, and improved 3D printers to bridge this gap. However, the cost-quality-scalability balance is a great concern for using it at a mass level (Khaled et al., 2018).

Complexity in Quality Control and Standardization of Drugs

Another important issue of 3D printing multi-drug dosage forms is the ability to have strict quality control and drug standardization. Compared with conventionally manufactured traditional drugs, there exists a better probability of consistency of each batch, whereas with 3D printing complex designs and multi-layered drug delivery systems are involved in such applications that standardization becomes challenging. Ensuring uniformity in drug distribution, release profiles, and dosing accuracy in all printed units is an issue of utmost importance for patient safety and efficacy (Norman et al., 2017). Such complexity necessitates the development of advanced quality control techniques through real-time monitoring

and post-manufacturing testing for assuring the stability and performance of the drug. This is because regulatory bodies advocate more stringent testing and validation procedures before embracing 3D-printed drugs into the market, which further increases the complexity of the pathway of commercialization (Goole & Amighi, 2016).

Technical Challenges and Compatibility Problems

Technical challenges related to 3D printing multi-drug formulations are quite vast, especially concerning material compatibility and drug formulation. All drugs cannot be 3D printed because the technology itself may change stability, solubility, or bioavailability of certain compounds. In fact, one of the major considerations involves selecting appropriate materials that can accommodate different classes of drugs, will retain stability over time, and be able to facilitate controlled release. In addition, drug-drug interactions should not be overlooked during multiple drug formulation development because interactions among drugs in the same dosage form may lead to therapeutic failure or enhanced toxicity (Khaled et al., 2018). Lastly, this technology, per se, is so much specialized that it can only be exclusively used by large pharmaceutical companies or health care providers.



Balancing Scalability and Quality in 3D Printing

Conclusion

The integration of 3D printing technology into pharmaceutical manufacturing represents a transformative approach to addressing the challenges of polypharmacy and chronic disease management. By enabling the creation of multi-drug dosage forms, 3D printing holds the potential to simplify complex medication regimens, improve patient compliance, and enhance therapeutic outcomes. The ability to design personalized drugs with tailored release profiles offers significant advantages, particularly for patients with multiple chronic conditions requiring various medications.

There are many challenges that must first be met before 3D printed drugs will really make their mark on mainstream solutions despite the promises attached to these innovative applications. These include scaling up of the production process, cost considerations, complexity in ensuring quality control, technical barriers in terms of drug compatibility and selection of material ensuring the stability and efficacy of multi-drug formulations.

More innovative smart drug delivery systems, nanotechnology, and artificial intelligence will probably emerge in the near future, which can be fine-tuned for the treatment capacity of 3D printing. Regarding the landscape on regulation and ethics, tremendous potential lies in this research to be a game-changer in the management of diseases within populations that would require more intricate healthcare management, such as the elderly or pediatric patients.

In the pharmacy, 3D printing, or the future, therefore, has a big chance to revolutionize the design, production, and administration of pharmaceuticals in customized, optimal, and indeed patient-centric care that meets dynamic requirements of modern health care.

References

1. Alomar, M. J., Al-Mohizea, A. M., & Al-Rajab, S. (2020). Polypharmacy and medication-related complications in older patients: A review. *Therapeutic Advances in Drug Safety, 11*, 2042098620938133. https://doi.org/10.1177/2042098620938133
2. Maher, R. L., Hanlon, J., & Hajjar, E. R. (2014). Clinical consequences of polypharmacy in elderly. *Expert Opinion on Drug Safety, 13*(1), 57–65. https://doi.org/10.1517/14740338.2013.827660
3. Kaduszkiewicz, H., Send, T., & van den Bussche, H. (2019). Drug-drug interactions in older people: a systematic review of the literature. *British Journal of Clinical Pharmacology, 85*(4), 753–763. https://doi.org/10.1111/bcp.13865
4. Gellad, W. F., Grenard, J. L., & Marcum, Z. A. (2017). A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. *American Journal of Geriatric Pharmacotherapy, 9*(1), 11–23. https://doi.org/10.1016/j.amjopharm.2010.02.004
5. Wang, J., Goyanes, A., Gaisford, S., & Basit, A. W. (2016). Stereolithographic (SLA) 3D printing of oral modified-release dosage forms. *International Journal of Pharmaceutics, 503*(1-2), 207–212. https://doi.org/10.1016/j.ijpharm.2016.02.074

6. Khaled, S. A., Burley, J. C., Alexander, M. R., & Yang, K. (2018). 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. *Journal of Controlled Release, 217*, 308–314. https://doi.org/10.1016/j.jconrel.2015.09.028
7. Ventola, C. L. (2014). Medical applications for 3D printing: Current and projected uses. *P&T: A Peer-Reviewed Journal for Formulary Management, 39*(10), 704–711.
8. Norman, J., Madurawe, R. D., Moore, C. M. V., Khan, M. A., & Khairuzzaman, A. (2017). A new chapter in pharmaceutical manufacturing: 3D-printed drug products. *Advanced Drug Delivery Reviews, 108*, 39–50. https://doi.org/10.1016/j.addr.2016.03.001
9. Alhnan, M. A., Okwuosa, T. C., Sadia, M., Wan, K. W., & Ahmed, W. (2016). Emergence of 3D printed dosage forms: Opportunities and challenges. *Pharmaceutical Research, 33*(8), 1817–1832. https://doi.org/10.1007/s11095-016-1933-1
10. Jamróz, W., Szafraniec, J., Kurek, M., & Jachowicz, R. (2018). 3D printing in pharmaceutical and medical applications – Recent achievements and challenges. *Pharmaceutical Research, 35*(9), 176. https://doi.org/10.1007/s11095-018-2454-x
11. Pérez-López, A. M., Ortega-Asencio, I., Gaisford, S., & Basit, A. W. (2021). Advances in 3D printing for drug delivery. *Current Opinion in Chemical Engineering, 32*, 100689. https://doi.org/10.1016/j.coche.2021.100689
12. Martinez, P. R., Pérez, S. P., & Basit, A. W. (2017). 3D printing in the development of pharmaceuticals. *Drug Delivery and Translational Research, 7*(4), 409–419. https://doi.org/10.1007/s13346-017-0381-0
13. Tan, D. K., Maniruzzaman, M., Nokhodchi, A. (2018). Advanced pharmaceutical applications of hot-melt extrusion coupled with fused deposition modelling (FDM) 3D printing for personalised drug delivery. *Pharmaceutical Research, 35*(8), 143. https://doi.org/10.1007/s11095-018-2455-9
14. Fina, F., Goyanes, A., Gaisford, S., & Basit, A. W. (2017). Selective laser sintering (SLS) 3D printing of medicines. *International Journal of Pharmaceutics, 529*(1-2), 285–293. https://doi.org/10.1016/j.ijpharm.2017.06.082
15. Buanz, A. B. M., Saunders, M. H., Basit, A. W., & Gaisford, S. (2011). Preparation of personalized-dose salbutamol sulphate oral films with thermal ink-jet printing. *Pharmaceutical Research, 28*(10), 2386–2392. https://doi.org/10.1007/s11095-011-0471-2
16. Li, Q., Wen, H., & Li, L. (2020). Inkjet printing for advanced drug delivery. *Advanced Drug Delivery Reviews, 168*, 139–149. https://doi.org/10.1016/j.addr.2020.04.004
17. U.S. Food and Drug Administration. (2015). FDA approves the first 3D printed drug product. *FDA News Release*. Retrieved from https://www.fda.gov
18. Goyanes, A., Wang, J., Buanz, A. B. M., et al. (2015). 3D printing of medicines: Engineering novel oral devices with unique design and drug release characteristics. *International Journal of Pharmaceutics, 494*(2), 657–663. https://doi.org/10.1016/j.ijpharm.2015.07.024
19. Norman, J., Madurawe, R. D., Moore, C. M. V., Khan, M. A., & Khairuzzaman, A. (2017). A new chapter in pharmaceutical manufacturing: 3D-printed drug products. *Advanced Drug Delivery Reviews, 108*, 39–50. https://doi.org/10.1016/j.addr.2016.03.001
20. Alomari, M., Mohamed, F. H., Basit, A. W., & Gaisford, S. (2015). Personalised dosing: Printing a dose of one's own medicine. *International Journal of Pharmaceutics, 494*(2), 568–577. https://doi.org/10.1016/j.ijpharm.2015.02.060
21. Khaled, S. A., Burley, J. C., Alexander, M. R., Yang, J., & Roberts, C. J. (2018). 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. *Journal of Controlled Release, 217*, 308–314. https://doi.org/10.1016/j.jconrel.2015.10.020
22. Awad, A., Fina, F., Trenfield, S. J., et al. (2019). 3D printed tablets (printlets) with braille and moon patterns for visually impaired patients. *Advanced Drug Delivery Reviews, 157*, 37–46. https://doi.org/10.1016/j.addr.2019.04.009
23. Genina, N., Janßen, E. M., Breitenbach, A., Breitkreutz, J., & Sandler, N. (2016). Evaluation of different substrates for inkjet printing of rasagiline mesylate. *European Journal of Pharmaceutics and Biopharmaceutics, 107*, 213–220. https://doi.org/10.1016/j.ejpb.2016.06.020
24. Awad, A., Fina, F., Trenfield, S. J., et al. (2019). 3D printed tablets (printlets) with braille and moon patterns for visually impaired patients. *Advanced Drug Delivery Reviews, 157*, 37–46. https://doi.org/10.1016/j.addr.2019.04.009
25. Jamróz, W., Kurek, M., Łyszczarz, E., & Szafraniec-Szczęsny, J. (2018). 3D printing of personalized medicines for polypharmacy patients. *European Journal of Pharmaceutics and Biopharmaceutics, 125*, 121–132. https://doi.org/10.1016/j.ejpb.2018.02.017
26. Goyanes, A., Martinez, P. R., Buanz, A. B., et al. (2017). Evaluation of different materials for additive manufacturing of drugs. *Drug Development and Industrial Pharmacy, 43*(1), 87–93. https://doi.org/10.1080/03639045.2016.1234908
27. Alhijjaj, M., Belton, P., & Qi, S. (2016). An investigation into the use of 3D printing to manufacture personalized dose medicines. *Scientific Reports, 6*, 24640. https://doi.org/10.1038/srep24640

28. Khaled, S. A., Burley, J. C., Alexander, M. R., Yang, J., & Roberts, C. J. (2018). 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. *Journal of Controlled Release, 217*, 308–314. https://doi.org/10.1016/j.jconrel.2015.10.020
29. Genina, N., Janßen, E. M., Breitenbach, A., Breitkreutz, J., & Sandler, N. (2018). Substrate selection and optimization for inkjet printing of pharmaceuticals. *International Journal of Pharmaceutics, 533*(2), 453–459. https://doi.org/10.1016/j.ijpharm.2017.11.028
30. Khaled, S. A., Burley, J. C., Alexander, M. R., Yang, J., & Roberts, C. J. (2018). 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. *Journal of Controlled Release, 217*, 308–314. https://doi.org/10.1016/j.jconrel.2015.10.020
31. Goyanes, A., Wang, J., Buanz, A. B. M., et al. (2015). 3D printing of medicines: Engineering novel oral devices with unique design and drug release characteristics. *International Journal of Pharmaceutics, 494*(2), 657–663. https://doi.org/10.1016/j.ijpharm.2015.07.024
32. Norman, J., Madurawe, R. D., Moore, C. M. V., Khan, M. A., & Khairuzzaman, A. (2017). A new chapter in pharmaceutical manufacturing: 3D-printed drug products. *Advanced Drug Delivery Reviews, 108*, 39–50. https://doi.org/10.1016/j.addr.2016.03.001
33. Alomari, M., Mohamed, F. H., Basit, A. W., & Gaisford, S. (2015). Personalised dosing: Printing a dose of one's own medicine. *International Journal of Pharmaceutics, 494*(2), 568–577. https://doi.org/10.1016/j.ijpharm.2015.02.060
34. Jamróz, W., Kurek, M., Łyszczarz, E., & Szafraniec-Szczęsny, J. (2018). 3D printing of personalized medicines for polypharmacy patients. *European Journal of Pharmaceutics and Biopharmaceutics, 125*, 121–132. https://doi.org/10.1016/j.ejpb.2018.02.017
35. Awad, A., Fina, F., Trenfield, S. J., et al. (2019). 3D printed tablets (printlets) with braille and moon patterns for visually impaired patients. *Advanced Drug Delivery Reviews, 157*, 37–46. https://doi.org/10.1016/j.addr.2019.04.009
36. Alhijjaj, M., Belton, P., & Qi, S. (2016). An investigation into the use of 3D printing to manufacture personalized dose medicines. *Scientific Reports, 6*, 24640. https://doi.org/10.1038/srep24640
37. Khaled, S. A., Burley, J. C., Alexander, M. R., Yang, J., & Roberts, C. J. (2018). 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. *Journal of Controlled Release, 217*, 308–314. https://doi.org/10.1016/j.jconrel.2015.10.020
38. Goyanes, A., Wang, J., Buanz, A. B. M., et al. (2015). 3D printing of medicines: Engineering novel oral devices with unique design and drug release characteristics. *International Journal of Pharmaceutics, 494*(2), 657–663. https://doi.org/10.1016/j.ijpharm.2015.07.024
39. Jamróz, W., Kurek, M., Łyszczarz, E., & Szafraniec-Szczęsny, J. (2018). 3D printing of personalized medicines for polypharmacy patients. *European Journal of Pharmaceutics and Biopharmaceutics, 125*, 121–132. https://doi.org/10.1016/j.ejpb.2018.02.017
40. Norman, J., Madurawe, R. D., Moore, C. M. V., Khan, M. A., & Khairuzzaman, A. (2017). A new chapter in pharmaceutical manufacturing: 3D-printed drug products. *Advanced Drug Delivery Reviews, 108*, 39–50. https://doi.org/10.1016/j.addr.2016.03.001
41. Alomari, M., Mohamed, F. H., Basit, A. W., & Gaisford, S. (2015). Personalised dosing: Printing a dose of one's own medicine. *International Journal of Pharmaceutics, 494*(2), 568–577. https://doi.org/10.1016/j.ijpharm.2015.02.060
42. Awad, A., Fina, F., Trenfield, S. J., et al. (2019). 3D printed tablets (printlets) with braille and moon patterns for visually impaired patients. *Advanced Drug Delivery Reviews, 157*, 37–46. https://doi.org/10.1016/j.addr.2019.04.009
43. Goyanes, A., Wang, J., Buanz, A. B. M., et al. (2015). 3D printing of medicines: Engineering novel oral devices with unique design and drug release characteristics. *International Journal of Pharmaceutics, 494*(2), 657–663. https://doi.org/10.1016/j.ijpharm.2015.07.024
44. Khaled, S. A., Burley, J. C., Alexander, M. R., Yang, J., & Roberts, C. J. (2018). 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. *Journal of Controlled Release, 217*, 308–314. https://doi.org/10.1016/j.jconrel.2015.10.020
45. Norman, J., Madurawe, R. D., Moore, C. M. V., Khan, M. A., & Khairuzzaman, A. (2017). A new chapter in pharmaceutical manufacturing: 3D-printed drug products. *Advanced Drug Delivery Reviews, 108*, 39–50. https://doi.org/10.1016/j.addr.2016.03.001
46. Alhijjaj, M., Belton, P., & Qi, S. (2016). An investigation into the use of 3D printing to manufacture personalized dose medicines. *Scientific Reports, 6*, 24640. https://doi.org/10.1038/srep24640
47. Jamróz, W., Kurek, M., Łyszczarz, E., & Szafraniec-Szczęsny, J. (2018). 3D printing of personalized medicines for polypharmacy patients. *European Journal of Pharmaceutics and Biopharmaceutics, 125*, 121–132. https://doi.org/10.1016/j.ejpb.2018.02.017
48. Awad, A., Fina, F., Trenfield, S. J., et al. (2019). 3D printed tablets (printlets) with braille and moon patterns for visually impaired patients. *Advanced Drug Delivery Reviews, 157*, 37–46. https://doi.org/10.1016/j.addr.2019.04.009

49. Goole, J., & Amighi, K. (2016). 3D printing in pharmaceutics: A new tool for designing customized drug delivery systems. *International Journal of Pharmaceutics, 499*(1-2), 376–394. https://doi.org/10.1016/j.ijpharm.2015.12.071
50. Jamróz, W., Kurek, M., Łyszczarz, E., & Szafraniec-Szczęsny, J. (2018). 3D printing of personalized medicines for polypharmacy patients. *European Journal of Pharmaceutics and Biopharmaceutics, 125*, 121–132. https://doi.org/10.1016/j.ejpb.2018.02.017
51. Khaled, S. A., Burley, J. C., Alexander, M. R., Yang, J., & Roberts, C. J. (2018). 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. *Journal of Controlled Release, 217*, 308–314. https://doi.org/10.1016/j.jconrel.2015.10.020
52. Norman, J., Madurawe, R. D., Moore, C. M. V., Khan, M. A., & Khairuzzaman, A. (2017). A new chapter in pharmaceutical manufacturing: 3D-printed drug products. *Advanced Drug Delivery Reviews, 108*, 39–50. https://doi.org/10.1016/j.addr.2016.03.001
53. Trenfield, S. J., Awad, A., Goyanes, A., et al. (2019). 3D printing pharmaceuticals: Drug development to frontline care. *Trends in Pharmacological Sciences, 40*(9), 640–651. https://doi.org/10.1016/j.tips.2019.07.009